Anticoagulation strategy in COVID Positive Patients [COVID-19]
Research type
Research Study
Full title
Anticoagulation strategy in COVID Positive Patients
IRAS ID
284956
Contact name
Henry Peake
Contact email
Sponsor organisation
Wirral University Teaching Hospitals
Duration of Study in the UK
0 years, 2 months, 11 days
Research summary
There has been a significant increase in the number of reported cases of thromboembolic events amongst patients with COVID-19 infection, not only in the scientific literature but in mainstream media too. There is concern that we do not understand the best strategy to avoid blood clot formation in this disease and this study aims to help answer the question of how best to do so.\n\nThis study will use already collected data from patients to identify the prevalence of thromboembolic events (i.e stroke, pulmonary embolism and deep vein thrombosis) amongst patients admitted to Arrowe park hospital with confirmed COVID-19 infection.\n\nPatient data is collected as a routine part of any patient admission. This study will use the data collected on all patients during the coronavirus pandemic to identify the proportion of patients who are at risk of thromboembolism. Further analysis of these patients, looking at their pre-existing conditions and blood work would be used to identify risk for developing thromboembolic events.\n\nWe have noticed a significant increase in the number of reported cases of blood clots amongst patients with COVID-19 infection, not only in the scientific literature but in mainstream media too. There is concern that we do not understand the best strategy to avoid blood clot formation in this disease and this study aims to help answer this. \nPatient data (blood tests, weight, height, X-rays etc.) is gathered as a routine part of any patient admission to help doctor treat patients. This study will use the data routinely collected to identify the number of patients who are at risk of blood clots. Any patient with a blood clot will be looked at in more detail to see if there are any potential risk factors or reasons for their clot development. \nWhen the concerns were raised about the number of blood clots in COVID-19 infections a change was made to our hospital policy, and the dosing of the medications used to prevent blood clots was increased. The study will also look at the risk of developing blood clots before and after the hospital policy for clot prevention was changed. \n
REC name
Yorkshire & The Humber - Bradford Leeds Research Ethics Committee
REC reference
20/YH/0207
Date of REC Opinion
13 Jul 2020
REC opinion
Further Information Favourable Opinion